Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiculoVax Lassa vaccine
- Development stage
- Preclinical
- Lead developer
- Emergent BioSolutions
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VesiculoVax Lassa vaccine is a VSV-based (vesicular stomatitis virus-vectored) prophylactic vaccine developed by Auro Vaccines and out-licensed to Emergent BioSolutions for the prevention of Lassa hemorrhagic fever. The vaccine utilizes the VesiculoVax platform, which employs an attenuated, replication-competent, negative-strand non-segmented RNA viral vector (specifically the N4CT1 backbone) engineered to express the Lassa virus glycoprotein complex (GPC) in its authentic form. This mechanism is designed to stimulate the immune system to produce potent neutralizing antibodies and elicit protective humoral immunity against the Lassa virus, a significant cause of viral hemorrhagic fever in West Africa and a potential bioterrorism agent. The vaccine has demonstrated efficacy in non-human primate challenge models and has completed IND-enabling toxicology studies.
- Brand names
- VesiculoVax
- Other names
- VesiculoVax LassaVSV-Lassa vaccineLassa virus vaccine (VSV-vectored)
02
Targets
GPC (Lassa virus glycoprotein complex)
Beyond the preview
Go deeper on VesiculoVax Lassa vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiculoVax Lassa vaccine.